A European Medicines Agency advisory panel has recommended a conditional approval for Zynteglo, bluebird bio’s lead gene therapy for thalassemia, a rare blood disorder.
Atai Life sciences has closed a $43 million second-round financing that will help it advance new medicines for mental illnesses derived from compounds in illicit drugs.
The UK government’s Biomedical Catalyst (BMC) programme has announced £23 million of funding for cutting edge health projects, including new software which enables radiologists to diagnose